
Hong Kong is expanding clinical trials of histotripsy, a non-invasive focused ultrasound treatment for tumors, targeting kidney cancer across three local medical centers.
AI-generated summary
Histotripsy is a non-invasive treatment that uses focused ultrasound to destroy tumours.
Hong Kong is expanding clinical trials of histotripsy, a non-invasive treatment that uses focused ultrasound to destroy tumours, as the city seeks to establish a role in developing the technology for kidney cancer.
The CUHK Medical Centre, Gleneagles Hospital Hong Kong and Hong Kong Sanatorium & Hospital would begin trials involving 30 patients targeting kidney cancer, the Li Ka Shing Foundation said on Wednesday.
The trials mark the latest development in Hong Kong business tycoon Li Ka-shing’s biotech investments, which have drawn international attention. “Hong Kong [becomes] the first city in Asia to validate the safety and efficacy of treating renal diseases with histotripsy,” the tycoon’s charity said in an emailed statement.
AI outlook — possibilities, not facts
Trials involving 30 patients targeting kidney cancer will begin.
Very likely · Within weeks

Recently, a nutritious lunch at Seongyeon High School was insufficient. A student purchased sizzling noodles from the deli department and found that the noodles were stained light green. Councilor Chen Yijun criticized Mayor Jiang Wanan's inspection for "treating the symptoms rather than the root cause." The school explained that the green marks were caused by the penetration of marker pen ink, and the manufacturer was penalized and fined NT$10,000.

In 2026, a Chinese expert consensus was released, recommending moderate-intensity statins combined with ezetimibe as the initial cholesterol-lowering strategy for extremely high-risk groups. With the inclusion of ezetimibe in the National Essential Medicines List, the accessibility of blood lipid management and combination medication for grassroots patients will be significantly improved.

A team from the University of Cambridge in the United Kingdom and the University of Oregon Health and Science in the United States published a study in Science and pointed out that cancer cells release PRDX1 protein to consume reactive oxygen species, causing immune T cells to lose the signal to initiate an attack. This discovery is expected to provide new directions for cancer immunotherapy, and related research is currently in the preclinical stage.

Wei Xilun, deputy director of the National Health Service of the Ministry of Health and Welfare, pointed out that the adult smoking rate in my country has dropped to 12.8%, and the number of smoking cessation services has increased year by year, with 373,000 services provided from January to August this year. The National Health Service plans to launch a "precision smoking cessation" model based on age groups and motivations in the future.

Jianqiao Xinyuan and Nippon Jusen Pharmaceutical jointly announced that the oral GnRH antagonist "Astin® Film-Coated Tablets 100 mg" has been approved by the Ministry of Health and Welfare as a new indication for endometriosis. Taiwan has become the first approved market in Asia to provide women of childbearing age with a new oral treatment option.

A man in his 50s traveled to Japan and developed acute urinary retention after taking commercially available cold medicine. Physician Chen Yuxin pointed out that the first-generation antihistamines and pseudoephedrine in cold medicines are the two main culprits of locking urine, and reminded four high-risk groups such as those with prostate hypertrophy and middle-aged and elderly men to be more vigilant when taking medicines.